A few years ago, Illumina ($ILMN) and Rady Children's Hospital (@RadyGenomics) collaborated to offer sequencing services for diagnosing critically-ill infants and toddlers.
Roughly 70% of rare diseases are genetic and they can take five years to diagnose.
As sequencing costs dropped and #AI got faster, this collaboration became Project Baby Bear: a pilot study for rWGS's diagnostic yield, clinical utility, and health economics in practice.
Several innovative companies joined Rady's in creating a rapid diagnostic pipeline.
@Clinithink contributed a natural language processing (#NLP) system to scour medical literature and the patient's EHR. Traditionally, this process would be carried out manually.
Genomic data would be fed to Diploid's (@diploidgenomics) AI-engine, MOON, which can suggest a causal #DNA variant out of ~45 million in just about five minutes.
This result would be verified on Fabric Enterprise; software by @FabricGenomics.
After the pilot, Rady's rWGS was covered by Blue Shield of California (~$5,000).
Resurfacing, @ARKInvest believes #AI-accelerated #genomic diagnostics should be less expensive and more accessible in local hospitals. You shouldn't need to travel to receive the best care.
So, where can we go from here?
A 2019 @AJHGNews article noted that the rare disease solve rate was <50% when using short read rWGS. The authors argued this rate could increase on long read systems given their ability to decipher hard-to-read variants.
Interestingly, Pacific Biosciences and Leiden University (@LUMC_Leiden), another hospital using Diploid's MOON, have a long-read/diagnostic summit series called SMRT Leiden.
Earlier this year, Invitae (@Invitae) acquired Diploid to (a) accelerate and lower the cost of its whole exome/genome services and (b) to democratize access to MOON for children's hospitals of all sizes.
Given the lower CapEx of PacBio sequencers and cost-declines associated w/ compute, we think some centers could profitably integrate decentralized long-read rWGS services, analyzable over the cloud w/ MOON.
Others have the flexibility to send samples to Invitae's central lab.
Moreover, we think Invitae's integration of genetic counseling AI / clinical workflow management tools (@cleargenetics), investments in telemedicine integration, and focus on rationalizing price, could galvanize rWGS adoption.
Altogether, rWGS is one of the most benevolent, impactful collisions of different areas of innovation and collaboration among various companies. #NGS#AI
A lab/hospital using PacBio, or another long-read platform, would need an LDT/certification to use such a system for diagnostic purposes as none currently are FDA cleared/CE-marked for diagnostic purposes.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
>90% of Americans over 45 have seen a Cologuard ad this week.
Fewer know of the test's parent company, Exact Sciences (EXAS), whose tests also guide care for the majority of early-stage breast cancer patients in the US.
Today, we released a 5-year model + article on Exact.
Our (base case) 2027 price target is $140 ($49 today). To get there, here's what we believe has to happen:
1. Exact's core business (Cologuard + Oncotype DX) grows on avg. >15% per year thru 2027, reaching $4B.
2. Exact achieves EBITDA positivity in the '23/'24 timeframe.
What we believe must happen (Cont.):
3. Exact uses its earnings to reinvest in its burgeoning pipeline, service its outstanding debt, and maintain its capital equipment.
4. Exact's pipeline, in aggregate, hits >$1B revenue by the end of 2027.
Now that @Quantum_Si has given us a peek under the hood of its protein #sequencing platform (Platinum), we can begin comparing actual results to theory.
A few months ago, I shared this paper that gave a theoretical framework for protein sequencing: pubs.acs.org/doi/10.1021/ac…
The author simulated how different factors, such as the # of readable amino acids (AAs) and the read length, would affect a protein sequencer's ability to unambiguously detect the 20,000 canonical human proteins in our bodies.
That chart is attached below.
I've marked in green where QSI currently stacks up. Based on its recent pre-print (linked below), Platinum can directly read seven (7) amino acids (F, Y, W, L, I, V, and R) with peptide reads that seem to max out around 20 AAs.
A recent publication by Dennis Lo et al applied long-read sequencing (LRS) in the prenatal screening (#NIPT) setting. It's a rather unorthodox technology/application pairing, and it's got me scratching my head a bit.
For context, earlier this year, Lo et al published a convolutional neural network ("the HK model") that enabled PacBio LRS devices to read methylation (5mC) across the entire genome with very high fidelity. This is important later.
@MJLBio@Sanctuary_Bio@Biohazard3737 Sure! I realize I was being a little vague with those statements. Generally, I think you're correct in your interpretation of the importance of P2 (great $/GB, but at a smaller scale) as well as duplex sequencing.
Something that is important to recognize, though ...
@MJLBio@Sanctuary_Bio@Biohazard3737 ... is how product deployment works differently between PacBio and Nanopore, which is partly an artefact of culture and of time in the public markets, in the public markets. I'm not advocating for one over the other with my next statements.
@MJLBio@Sanctuary_Bio@Biohazard3737 PacBio has been a public company for a long time. While the management has changed much since the failed Illumina merger, the familiarity with how to operate as a public company has not.
PacBio is more secretive and only unveils fully built-out commercial products.
I'd like to share my initial reaction to today's Berkeley Lights report. But first, I need to do some housekeeping. I can't comment on stock movements, share financial projections, or debate fair value.
Generally, I respect anyone who's put this much work into a topic. I won't pretend to have a clean rebuttal to every point. In my experience, beyond the hyperbole and hasty generalizations, there is some truth in these types of reports.
I want to soberly appraise those truths.
Also, I'd invite the subject-matter experts waiting in the wings to build off of this thread, add detail, or share their experiences. Ultimately, we're all after the same thing.
I will start with a few concessions and end with a few counterpoints to today's report: